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Edited by Lukas HuberAbstract In contrast to wtEGFR, its truncated version EGFR-
vIII transformed non-tumorigenic FDC-P1 cells only when
c-Myc was coexpressed. In nude mice, EGFRvIII/c-Myc coex-
pressing cells induced tumors, whereas wtEGFR-expressing
EGF-dependent FDC-P1 cells did not. EGFRvIII function was
required for both the induction and maintenance of tumor
growth. Cellular proliferation was inhibited by a selective EGFR
tyrosine kinase inhibitor indicating intrinsic tyrosine kinase
activities for both receptors. Unlike wtEGFR, constitutive sig-
naling by EGFRvIII was refractory to stimulation by the EGFR
ligands EGF and TGF-a. Summarized, EGFRvIII is a constitu-
tively active receptor tyrosine kinase whose transforming capac-
ity is lower than that of EGF-stimulated wtEGFR.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Tyrosine kinase inhibitor1. Introduction
EGFR is a receptor tyrosine kinase involved in the prolifer-
ation, diﬀerentiation and survival of epithelial cells, astrocytes,
and neurons [1]. The signal transduction cascade emanating
from the EGFR is induced by the binding of activating ligands
such as EGF and TGF-a, resulting in EGFR homo-/hetero
dimerization, autophosphorylation and subsequent activation
of downstream signal transduction molecules [2]. Using vari-
ous cellular model systems (both ﬁbroblastic and hemopoi-
etic), it has been shown that EGFR signaling can contribute
to cell transformation. In this process the EGFR is perma-
nently stimulated, for example through the autocrine produc-
tion of stimulating ligands [3,4]. Excess EGFR activity
resulting from such an autocrine loop or from a high EGFR
overexpression is implicated in a signiﬁcant proportion of hu-
man carcinoma types such as non-small cell lung cancer [5],Abbreviations: wtEGFR, wild-type growth factor receptor; EGFRvIII,
epidermal growth factor receptor variant III; tTA, tetracycline-
regulated transactivator protein; siRNA, small interfering RNA;
VEGF2R, vascular endothelial growth factor receptor
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doi:10.1016/j.febslet.2007.04.077breast cancer [6], and prostate cancer [7]. EGFR is also in-
volved in the development of glioblastoma multiforme [8,9].
There, the predominant mechanism is the ampliﬁcation of
the EGFR gene leading to EGFR overexpression, which is
found in about 40% of patients. Interestingly, only in about
half of these cases the ampliﬁed EGFR gene encodes the
wild-type growth factor receptor (wtEGFR). In the other half,
mutant EGFR forms are coexpressed with the wtEGFR. Thus,
the EGF-receptor is involved in two distinct progression steps
in glioblastoma where ampliﬁcation of the wtEGFR is fol-
lowed by acquisition of activating alterations in the EGFR
gene structure [10]. The most common mutation of EGFR
found in glioblastoma is the N-terminal truncation known as
variant III (EGFRvIII). Epidermal growth factor receptor var-
iant III (EGFRvIII) lacks the amino acids 6–273 encoded by
exons 2–7 [11]. Over the last 10 years the transforming poten-
tial as well as the mechanisms underlying transformation by
EGFRvIII and wtEGFR have been investigated [12]. One
striking diﬀerence between the two EGFR forms is that
EGFRvIII displays signaling activity in the absence of stimu-
lating ligands. In accordance with this observation, EGFRvIII
can transform cells of various types without the involvement of
EGFR-stimulating ligands [13–17]. However, very little is
known about binding of EGF or TGF-a to EGFRvIII
[16,18]. Only one study reported a weak binding of TGF-a
to EGFRvIII that resulted in cellular stimulation [13].
The objective of this study was to compare the transforming
potential of EGFRvIII with that of wtEGFR. For this pur-
pose, a doxycycline-regulated expression system was estab-
lished for both receptors in IL-3-dependent, non-tumorigenic
FDC-P1 cells. The resulting clones were characterized with
respect to their sensitivity to a speciﬁc EGFR inhibitor,
response to exogenousgrowth factor, and tumorigenicpotential.2. Materials and methods
2.1. Transfection and cloning of FDC-P1 cell derivatives expressing
EGFRvIII and wtEGFR
Modiﬁed FDC-P1 cells derived from mouse myelomonocytic pro-
genitors [19] were used as recipient cells; two diﬀerent cell lines (FtL
and FtLm) were used as parentals (for generated and used cell lines
see Table 1). Additionally to their normal growth medium [19],
untransfected cells received 1% (v/v) IL-3 supernatant of X63Ag8-
653-IL3 cells [20], wtEGFR-transfected cells 20 ng/ml EGF (Promega).
Plasmids were introduced into cells via electroporation and anti-
biotic selection with 400 lg/ml hygromycin B (Invitrogen) in presence
of 1% (v/v) IL-3 was performed for 7–10 days. After antibioticblished by Elsevier B.V. All rights reserved.
Table 1
Description of cell lines generated
FDC-P1 derivative Introduced genes Growth factor
dependence
Tumorigenicity Drug sensitivity towards
BIBX1382BS (in absence of IL-3)a
FDC-P1 – IL-3  n.a.
FtL tTA IL-3  n.a.
FtLm tTA, c-MYC IL-3  n.a.
F/Lauto wtEGFR, TGF-a  + +
FtL-VEGF2R VEGF2R, tTA  + 
FtL-wtEGFR wtEGFR, tTA EGF  +
FtL-EGFRvIII EGFRvIII, tTA IL-3  n.a.
FtLm-wtEGFR wtEGFR, tTA, c-MYC EGF  +
FtLm-EGFRvIII EGFRvIII, tTA, c-MYC  + +
tTA tetracycline-regulated transactivator protein; n.a., not applicable.
aDrug sensitivity determined using both Cytosensor and MTS-assays.
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were cloned in 1% (w/v) Methocel (Invitrogen). Finally, clonal identity
was veriﬁed by Southern blotting.
2.2. MTS-assay
Cells were seeded in triplicates in 96-well assay plates at 20.000 cells
per well in 100 ll standard medium. Clones overexpressing wtEGFR
were supplemented with 8 ng/ml EGF, whereas clones overexpressing
EGFRvIII did not receive any additional growth factors as pilot exper-
iments have shown that addition of EGF to EGFRvIII-expressing cells
resulted in no change of proliferation rate. Determination of IC50 val-
ues was done using seven dilution steps. Doxycycline (Sigma) concen-
trations ranged from 1010 to 103 g/l in steps of one magnitude.
BIBX1382BS is a proprietary EGFR tyrosine kinase inhibitor from
Boehringer-Ingelheim [21]. After 48 h, viable cells were determined
using a MTS-mix (Promega).
2.3. FACS-analysis
FACS-analysis was performed as previously described [17]. Primary
antibodies were Ab-1 – detects both wtEGFR and EGFRvIII and Ab-
5 – recognizes exclusively wtEGFR (both from CALBIOCHEM), the
secondary antibody was F 261 (DAKO). Evaluation was done using
the software ‘‘Cell Quest’’ (Becton Dickinson).
2.4. Cytosensor experiments
A suspension of 4 · 106 cells per 300 ll was prepared and mixed
gently with 100 ll freshly molten agarose cell entrapment medium at
37 C as described in the manufacturer’s protocol. 10 ll of this mix
was transferred into the center of each cell capsule. After solidiﬁcation
of the cell/agarose mixture, the capsules were placed into the Cytosen-
sor Microphysiometer (Molecular Devices). Prior to measurement,
cells were equilibrated with medium for 1–2 h until a steady baseline
was observed. Afterwards inhibitor/growth factors were added to the
media and the pH-change was monitored.
2.5. RT-PCR
Total RNA was prepared with TRIzol (Invitrogen) according to the
manufacturer’s protocol. Using the Superscript Kit (Invitrogen)
cDNA was prepared. Approximately 1 lg cDNA was used for PCR,
in which a fragment of 145 bp length speciﬁc for EGFRvIII (exon 2–
7 overlap) is ampliﬁed.
Primers: 5 0-GGAGGAAAAGAAAGGTAATTATGTGGT-3 0 and
5 0-TATTCCGTTACACACTTTGCGG-3 0.
2.6. RNA interference
Cells that were used as IL-3 controls were grown for 48 h in presence
of IL-3. wtEGFR-expressing cells also received EGF. 5000 cells per 96-
well were transfected with small interfering RNA (siRNA) using Oligo-
fectAMINE according to the manufacturer’s instruction. Forty-eight
hours later the number of proliferating cells was determined using
the MTS-assay as described above.
siRNA oligonucleotides (Dharmacon) sequences were anti-human
myc: 5 0-AACUUCUACCAGCAGCAGCAG-3 0 and a scrambled
(negative) control: 5 0-AAUACCCUUCAGCAGCAGCAG-3 0.To exclude a general toxicity of the applied c-MYC siRNA, cells
were also treated in the presence of IL-3. The level of c-MYC down-
regulation was determined using quantitative PCR. Western blotting
could not be performed as there is no antibody available that does
not cross-react with mouse c-MYC.
2.7. Tumorigenicity in athymic mice
wtEGFR, EGFRvIII and FtLm cells were tested for tumorigenicity
in 5–10 week old female Hsd:NMRI-nu/nu mice (Harlan, The Nether-
lands). For this, 100 ll of a cell suspension (at 107 cells per ml in
PBS + 5% FCS) of each cell line was injected s.c. into the right hind
ﬂank of three mice. Tumors were measured three times a week with
a calliper. To monitor side eﬀects of treatment, mice were inspected
daily for abnormalities and weighed three times a week. The experi-
ment ran for 3 months. HP-b-CD (hydroxypropyl-beta-cyclodextrin)
was used as vehicle.
2.8. Therapeutic experiment
When tumors were established and had reached diameters of
approximately 5–10 mm, administration of compounds was started.
Doxycycline was administered via drinking water whereas
BIBX1382BS was given once per day by gavage needle. Animals were
killed or taken out of study when tumors had grown to large volumes
(between 1200 and 2000 mm3) or when the animals’ general condition
had deteriorated (e.g., progressive weight loss), possibly as a conse-
quence of compound administration.
Absolute tumor volumes were expressed as relative tumor volumes
(Vrel), i.e., normalized with respect to the tumor volume at the start
of the treatment (Vrel = T/Tstart) and as speciﬁc relative tumor volumes
(referred to as T/C [%]), i.e., as the mean relative volume of a group of
compound-treated tumors in % of the mean relative volume of vehicle
control tumors (T/C [%] = 100 Æ Vrel substance-treated/Vrel vehicle-trea-
ted). Evaluation of responses was based on Vrel- and T/C [%]-values
determined on the day following the ﬁnal treatment. Tumor-bearing
animals that died during an experiment or were removed from the
experiment prematurely for other reasons were not considered for
the calculation of mean tumor volumes. A ﬁnal T/C [%]-value below
50% was regarded as tumor response.3. Results
3.1. EGFRvIII expression is insuﬃcient to render FDC-P1 cells
IL-3-independent
The transient and massive cell death that occurred in all
transfected FDC-P1 cultures in response to IL-3-withdrawal
indicates that an eﬃcient selection process preceded the emer-
gence of IL-3-independent cells (for generated and used cell
lines see Table 1). To distinguish between a general heterogene-
ity of the transfected FDC-P1 cells per se – which might be
responsible for this eﬃcient selection process – or secondary
mutational events that occur stochastically in some cells,
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to the IL-3-withdrawal. By contrast, in the normal protocol
IL-3-independent clones were selected from hygromycin-resis-
tant bulk cultures (expressing either wtEGFR or EGFRvIII in
a doxycycline-repressed manner), prior to cloning. Less than
10% of the hygromycin-resistant clones could be expanded to
IL-3-independent cultures. However, these clones either died
rapidly in response to IL-3 withdrawal or persisted for weeks
without growing before they died. Importantly, those clones
that did proliferate in the absence of IL-3 were not aﬀected
by cell death even at early stages of plating, suggesting that
their selection did not depend on the acquisition of secondary
mutations but that the heterogeneous clonal growth resulted
from pre-existing diﬀerences.
We found that transformation of FDC-P1 cells by EGFR-
vIII required the coexpression of c-Myc. To rule out the pos-
sibility that inadequate EGFRvIII expression levels were
responsible for the failure of EGFRvIII to induce the selection
of IL-3-independent FDC-P1 cells in the absence of coexpres-
sed c-Myc, we compared EGFR expression levels by FACS
analysis. Neither expression of wtEGFR nor EGFRvIII was
detected in hygromycin-resistant cultures that had not been
adapted to IL-3-independent growth. This held even true for
cultures that displayed high EGFR expression after adaptation
to IL-3-independent growth (data not shown). Next, we inves-
tigated whether IL-3 growth independence required a thresh-
old level of EGFRvIII expression. Clones of hygromycin-
resistant FtL-EGFRvIII transfectants were subjected to a
reduction of IL-3 levels to select for clones that showed pro-
longed survival, which could be indicative of high EGFRvIII
expression. Individual clones were subsequently analyzed by
RT-PCR, using primers speciﬁc for EGFRvIII cDNA. A dis-
tinct band indicative of the EGFRvIII transcript was detected
in several clones, suggesting that EGFRvIII cDNA is indeed
transcribed in FtL-EGFRvIII cells (see Supplemental Fig. 1).
The fact that these clones eventually died in the absence of
IL-3 indicates that EGFRvIII on its own is not suﬃcient to
fully replace IL-3-receptor-mediated survival and proliferation
signals. To further test this hypothesis, c-myc levels were
downregulated by siRNA in the cell lines. Proliferation of
Ftlm-EGFRvIII cells was reduced by approximately 50%
when c-MYC expression was downregulated (this is approxi-Fig. 1. Inﬂuence of c-Myc knockdown on proliferation of EGFRvIII-expre
diﬀerent cell lines. Untransfected FDC-P1 cells in presence of IL-3 were setmately equivalent to the transfection eﬃciency in FDC-P1
cells). Neither FtLm-wtEGFR, that coexpress wtEGFR and
c-Myc, FtL-wtEGFR, that only overexpress wtEGFR nor
the parental cells were aﬀected by siRNA to c-myc (Fig. 1).
3.2. EGFRvIII-signaling is refractory to further stimulation by
EGF and TGF-a
The observation that EGFRvIII supports IL-3 independent
cell survival and proliferation in the absence of cognate ligands
indicates that constitutive signaling by EGFRvIII is responsi-
ble for these cellular eﬀects. Nevertheless, it was possible that
the EGFR-activating ligands EGF and TGF-a superstimulate
the constitutive activity of EGFRvIII. Stimulation of intracel-
lular signal transduction accelerates cellular metabolism that
can be detected by the Cytosensor Microphysiometer
(Molecular Devices), which records alterations in cellular
metabolism as changes in the rate of medium acidiﬁcation
[22,23]. Following exposure to EGF, FtLm-wtEGFR cells
strongly increased the rate of medium acidiﬁcation, whereas
the EGFR-deﬁcient FtLm cells showed no response. Impor-
tantly, FtLm-EGFRvIII cells, like wtEGFR-deﬁcient FtLm
cells, were refractory to stimulation by high EGF and TGF-
a concentrations (Fig. 2). These results indicate that EGF or
TGF-a do not activate intracellular signal transduction via
EGFRvIII.
3.3. Intracellular EGFRvIII-signaling is constitutively active and
sensitive to a speciﬁc EGFR receptor kinase inhibitor
To demonstrate that the constitutive signaling by EGFRvIII
could be inhibited, the EGFR tyrosine kinase inhibitor
BIBX1382BS [21] was used in a Cytosensor experiment.
The eﬀect of BIBX1382BS exposure on the metabolic rate of
cells was assessed in medium devoid of growth factors. The
inhibitor had no eﬀect on the metabolic activity of wtEGFR-
deﬁcient FtLm cells but suppressed the metabolic activity of
FtLm-EGFRvIII cells (Fig. 3). These results suggested
that BIBX1382BS inhibited the constitutive intracellular
EGFRvIII-signaling. The inhibition of EGFRvIII-signaling
by BIBX1382BS is reversible, as the medium acidiﬁcation
rate recovered to pre-treatment levels after washing out
BIBX1382BS (Fig. 3). The delay of recovery after removal of
BIBX1382BS correlated with the previously administeredssing cells. An MTS-assay was used to determine the response of the
as 100% control.
Fig. 2. Addition of EGF or TGF-a only aﬀects wtEGFR-expressing cells. The black arrow symbolizes the duration of ligand addition in a
Cytosensor experiment, the open arrow marks the change to normal medium devoid of exogenous ligand. Concentration of ligands for FtLm-
wtEGFR cells: 20 ng/ml TGF-a (j), 20 ng/ml EGF (h); FtLm-EGFRvIII cells: 100 ng/ml TGF-a (d), 100 ng/ml EGF (s); FtLm cells: 20 ng/ml
TGF-a (m), 20 ng/ml EGF (n). (¤) indicates unstimulated FtLm-wtEGFR cells. FtL-wtEGFR cells react similar compared with FtLm-wtEGFR
cells (see Supplemental Fig. 2).
Fig. 3. BIBX1382BS inhibits EGFRvIII-signaling in EGFRvIII-expressing cells reversibly in a concentration-dependent manner. The black arrow
symbolizes the duration of inhibitor addition in a Cytosensor experiment, the open arrow marks the change to normal medium devoid of inhibitor.
Concentrations of BIBX1382BS for FtLm-EGFRvIII cells: 0.1 lM (s), 0.3 lM (d), 1 lM (h), 3 lM (j), 10 lM (¤) and for FtLm cells 3 lM
inhibitor (n).
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those made in earlier experiments, in which FtLm-wtEGFR
cells were stimulated with EGF in the absence or presence of
BIBX1382BS (see Supplemental Fig. 2).3.4. EGFRvIII-dependent tumorigenicity of FtLm-EGFRvIII
cells in NMRI-nu/nu mice
Three clones each from FtLm-EGFRvIII, FtLm-wtEGFR,
and the untransfected parental cell line FtLm, respectively,
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conﬁrmed by Southern Blotting. Each clone was injected into
the hind ﬂank of three nude mice. EGFRvIII-expressing cells
produced tumors in one- to two-thirds of the injected animals,
whereas wtEGFR-expressing cells and the parental cell line
were non-tumorigenic after 90 days (data not shown). The
clone with the highest tumor take rate was chosen and an
ex vivo culture of it was established. Clonal identity was recon-
ﬁrmed by Southern blotting. Both sensitivity towards
BIBX1382BS and doxycycline (tet-induced down-regulation
of EGFRvIII) was comparable to the original cell line. These
ex vivo cells were tumorigenic in all injected mice and were used
for subsequent therapeutic experiments (Figs. 4A and 5A).
3.5. EGFRvIII is necessary for the maintenance of FtLm-
EGFRvIII tumor growth
To address the question whether continuous expression of
EGFRvIII is required for tumor maintenance, mice bearing
FtLm-EGFRvIII tumors were either treated with the EGFRFig. 4. Inﬂuence of doxycycline-induced down-regulation of EGFRvIII expr
with constitutive wtEGFR expression (B). Starting on day one, six well-es
tumors (B) were treated with doxycycline (j) or with the vehicle HP-beta-C
treatment. The dashed horizontal line corresponds to a relative tumor volum
the start of treatment. For detailed description of cell lines used see Table 1
Fig. 5. BIBX1382BS sensitivity of tumors derived from FtLm-EGFRvIII (A
driven FtLm-EGFRvIII tumors (A), and, as controls, six wtEGFR-driven F/
were treated with BIBX1382BS (n) or with the vehicle HP-beta-CD (h). FtLm
at 60 mg/kg/d p.o., F/Lauto tumors received only 30 mg/kg/d p.o. BIBX1382
of one, i.e. no change of the tumor volume relative to the volume at the statyrosine kinase inhibitor, BIBX1382BS, or with doxycycline
to repress transcription of EGFRvIII (Table 2). While
FtLm-EGFRvIII tumors grew steadily in vehicle control mice,
administration of doxycycline induced complete regression of
all tumors within 1 week (Fig. 4A). The fact that doxycycline
did not aﬀect growth of F/Lauto tumors rules out non-speciﬁc
cytotoxicity of doxycycline towards FDC-P1-derived tumor
cells as a cause of tumor regression (Fig. 4B). However, when
administered nearly at MTD (maximal tolerated dose, 70 mg/
kg/d in NMRI-nu/nu mice), BIBX1382BS caused only a slight
reduction of the FtLm-EGFRvIII tumor growth rate,
although it induced, even at a lower daily dose, regression of
F/Lauto tumors within 4 days (Fig. 5A and B). That
BIBX1382BS acts in vivo speciﬁcally on EGFR and is not gen-
erally cytotoxic was demonstrated by the complete insensitivity
of FtL-VEGF2R tumors to BIBX1382BS treatment (Fig. 5C).
In summary, these results show that the growth of established
FtLm-EGFRvIII tumors depends strictly on EGFR kinase
function.ession on tumor growth of FtLm-EGFRvIII (A) and F/Lauto tumors
tablished FtLm-EGFRvIII tumors (A) and, as controls, six F/Lauto
D (h). Individual relative tumor volumes were plotted over days of
e of one, i.e., no change of the tumor volume relative to the volume at
.
), F/Lauto (B) or FtL-VEGF2R (C). Six well-established EGFRvIII-
Lauto tumors (B), and six VEGF2 R-driven FtL-VEGF2R tumors (C),
-EGFRvIII and FtL-VEGF2R tumors were treated with BIBX1382BS
BS. The dashed horizontal line corresponds to a relative tumor volume
rt of treatment. For detailed description of cell lines used see Table 1.
Table 2
T/C and Vrel values as measurement of anti-tumor eﬃcacy
Cell line BIBX1382BS-treated Doxycycline-treated
Animal 1 2 3 1 2 3
T/C [%] Vrel T/C [%] Vrel
FtLm-EGFRvIII 75.1 46.8 50.9 3.96 0 0 0 0
F/Lauto 0 0 0 0 92.8 95.8 101.2 7.17
FtL-VEGF2R 73.2 73.8 73.8 12.41 n.d. n.d. n.d. n.d.
n.d., not determined; Each of these cell lines was injected into three NMRI-nu/nu mice.
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The mechanism(s) involved in transformation of cells by
EGFRvIII are still not completely understood. Several studies
have shown that signaling by EGFRvIII diﬀers from that of
wtEGFR. Firstly, the downstream signal transducers utilized
by EGFRvIII may diﬀer from the molecules recruited by
wtEGFR [16,24–26]. While EGFRvIII exhibits constitutive
tyrosine phosphorylation characteristic of an activated state
[15,17], the overall amount of phosphotyrosine in EGFRvIII
is lower than in ligand-stimulated wtEGFR [27]. This observa-
tion is consistent with the possibility of altered downstream
signaling of EGFRvIII. Finally, it has been suggested that
the intrinsic tyrosine kinase activity of EGFRvIII may not
be responsible for the molecule’s biological activity [13], a
statement that diﬀers from the conclusions of most other re-
ports e.g., [27,28]. Taken together, these observations suggest
that EGFRvIII may not just be a constitutively active version
of wtEGFR but may exhibit distinct signaling mechanisms uti-
lizing diﬀerent protein partners. Most of the apparent con-
tradictions between the results presented in the various
reports may also be due to diﬀerences in the cellular systems
used for experimentation.
In the present study we have used FDC-P1 cells derived
from mouse myelomonocytic progenitors [19,29] as recipient
cells, as they do not express endogenous EGF-receptors. For
propagation, FDC-P1 cells require the addition of growth fac-
tors such as IL-3 [19]. Because of their dependence on exoge-
nous growth factors they are non-tumorigenic in nude mice
[30,31]. Earlier studies have shown that recombinant deriva-
tives of FDC-P1 cells, which express human wtEGFR, can
also grow in vitro in the absence of IL-3, if supplemented with
EGF or TGF-a [29,32]. Coexpression of TGF-a together with
wtEGFR in an autocrine fashion renders the resulting cell line
F/Lauto tumorigenic in nude mice [29]. Therefore, FDC-P1
cells are an attractive system to assess the oncogenic potential
of EGFRvIII transfectants.
EGFRvIII in combination with c-Myc is suﬃcient for
growth autonomy. Interestingly, we noted that this is only
the case in a minority of hygromycin-resistant transfectants
after selection for IL-3 independent growth, indicating that
an adequately high expression level of EGFRvIII was needed.
This result is consistent with another study showing that only 1
in 104 transfected FDC-P1 cells expressed suﬃciently high
v-Fms levels to render the cells IL-3-independent [33].
Apparently, the eﬃcient transformation of FDC-P1 cells can
only be achieved by coexpression of EGFRvIII with c-Myc,
but not by EGFRvIII on its own. While single oncogenes
can have little eﬀect on cellular phenotypes, a pair of nuclear
and cytoplasmic oncogenes can be fully transforming and
make cells tumorigenic. This was ﬁrst demonstrated for thecombination of the nuclear Myc and the cytoplasmic Ras
[34]. A precedent for the cooperation of nuclear and cytoplas-
mic oncogenes in the transformation of immortalized bron-
chial epithelial cells is the combination of c-Myc with c-Raf
[35]. As EGFRvIII acts upstream of Ras and Raf, its cooper-
ation with Myc is in line with these observations. One explana-
tion for why EGFRvIII but not wtEGFR depends on ectopic
c-Myc expression in order to abrogate the IL-3-dependence of
FDC-P1 cells could either be that diﬀerent signal transduction
pathways are utilized by the two EGF-receptors [16,24,25] or a
diﬀerence in the intensity of signals emanating from the recep-
tors. The question of whether the combination of EGFRvIII
and c-Myc is really suﬃcient for the induction of growth
autonomy and tumorigenicity in FDC-P1 cells was addressed
by c-MYC siRNA experiments demonstrating that EGFRvIII
on its own is not suﬃcient to render FDC-P1 cells IL-3-inde-
pendent. Down-regulation of human c-MYC by siRNA
(reduction to 25% of original human c-MYC level) led to a sig-
niﬁcant decrease of FtLm-EGFRvIII proliferation (Fig. 2).
This eﬀect could be rescued by addition of IL-3. However,
depletion of human c-Myc in EGF-dependent FtLm-wtEGFR
cells resulted in no eﬀect on cellular proliferation.
In contrast to wtEGFR, the constitutive activity of EGFR-
vIII was refractory to superstimulation by EGF and TGF-a as
shown by measurement of the intracellular signal transduction
rate utilizing a Cytosensor Microphysiometer (Fig. 2). This
lack of superstimulation may have two reasons. Either ligands
may only bind with low aﬃnity to EGFRvIII, or binding of li-
gands has no inﬂuence on EGFRvIII-signaling. In contrast to
other studies [13], we observed that addition of excessive
amounts of ligand had no eﬀect on the downstream signaling
of EGFRvIII under these conditions.
Whether or not the biological activity of EGFRvIII depends
on its intrinsic tyrosine kinase activity has been a contentious
issue. While the majority of studies indicate that this is the case
[27,28,36], Batra et al. found that EGFRvIII is largely kinase-
defective and concluded that the molecule employs other
signaling mechanisms [13]. To address this issue, EGFRvIII-
expressing FDC-P1 cells were treated with the potent and
selective EGFR tyrosine kinase inhibitor, BIBX1382BS. The
drop of metabolic activity was observed, suggesting that the
constitutive intracellular EGFRvIII-signaling was inhibited.
The inhibition by BIBX1382BS was reversible and dosage-
dependent, as seen in the rate of medium acidiﬁcation to
pre-treatment levels after washing out BIBX1382BS. The delay
of recovery after removal of BIBX1382BS correlated with the
administered BIBX1382BS concentration. These observations
show that EGFRvIII possesses tyrosine kinase activity. This
ﬁnding is in agreement with the earlier observation that vi-
rally-transduced mutants of chicken EGFR (referred to as
v-erbB), which are similar to EGFRvIII in lacking N-terminal
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could demonstrate that EGFRvIII in combination with a con-
stitutively expressed c-Myc renders FDC-P1 cells tumorigenic,
it was not clear whether EGFRvIII is also required for the
maintenance of tumor growth.
For example, it is possible that EGFRvIII became superﬂu-
ous during tumorigenesis because of the acquisition of
additional genetic changes by tumor cells. Numerous studies
have already shown that growth autonomy of FDC-P1 cells,
induced by either autocrine or non-autocrine mechanisms, cor-
relates with full transformation and tumorigenicity after inoc-
ulation of the cells in syngeneic and nude mice [33,37,38]. The
tumorigenicity of the autonomous FDC-P1 cell lines coex-
pressing EGFRvIII and c-Myc demonstrates that these cells
are not an exception to that rule. The sensitivity of established
tumors towards doxycycline-induced down-regulation of
EGFRvIII shows that the maintenance of tumor growth, like
the maintenance of the growth autonomy in culture
(Fig. 4A), requires continued EGFRvIII expression. Addi-
tional support for this conclusion comes from the growth
reduction of tumors derived from FtLm-EGFRvIII cells in
NMRI-nu/nu mice via inhibition of the EGFRvIII tyrosine ki-
nase activity by BIBX1382BS. A full regression as seen with
F/Lauto (Fig. 5B) cannot be achieved with FtLm-EGFRvIII
cells as there exists an approximately 20-fold higher sensitivity
of F/Lauto cells (IC50: 15 nM) towards BIBX1382BS com-
pared with FtLm-EGFRvIII cells (IC50: 350 nM). Therefore,
inhibitor levels in tumor tissue are suﬃciently high to kill
F/Lauto but not FtLm-EGFRvIII cells, since the required
drug concentration for complete inhibition of growth of
FtLm-EGFRvIII-derived tumors in NMRI nu/nu mice would
exceed by far the maximal tolerated dose of BIBX1382BS.
An obvious question arising from these ﬁndings is whether
EGFRvIII and Myc also cooperate in human tumors driven
by EGFRvIII. Ampliﬁcation of MYC and EGFRvIII genes
have been reported in glioblastoma where EGFRvIII was ﬁrst
discovered. Recently, coampliﬁcation of EGFR and MYC was
shown to be associated with bad prognosis in breast cancer
[39]. However, there is so far no evidence for the occurrence
of the ampliﬁcation of both genes in the same tumor [18].
Additional experiments are clearly needed to analyze whether
in EGFRvIII-positive human tumors, c-Myc expression is
deregulated by mechanisms other than gene ampliﬁcation.
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